Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

[1]  D. Demetrick,et al.  BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. , 2009, Archives of pathology & laboratory medicine.

[2]  B. Bastian,et al.  Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation , 2008, Pigment cell & melanoma research.

[3]  H. Nagatsuka,et al.  C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma , 2008, Virchows Archiv.

[4]  A. D. Van den Abbeele,et al.  Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Gutzmer,et al.  Prognostic Significance of Isolated HMB45 or Melan A Positive Cells in Melanoma Sentinel Lymph Nodes , 2007, The American journal of surgical pathology.

[6]  Narasimhan P. Agaram,et al.  L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.

[7]  D. Schadendorf,et al.  Imatinib in melanoma: a selective treatment option based on KIT mutation status? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Berking,et al.  Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR‐1, c‐kit) in nevi and melanoma , 2007, Journal of cutaneous pathology.

[9]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Mills,et al.  Anorectal malignant melanoma: morphologic and immunohistochemical features. , 2006, American journal of clinical pathology.

[11]  M. Atkins,et al.  Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.

[12]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[13]  J. Marshall,et al.  The role of c-kit and imatinib mesylate in uveal melanoma , 2005, Journal of carcinogenesis.

[14]  J. Lutzky,et al.  An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients , 2005, Melanoma research.

[15]  Adrian A Canutescu,et al.  Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling , 2005, Clinical Cancer Research.

[16]  S. Tripp,et al.  Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. , 2005, Human pathology.

[17]  D. Schadendorf,et al.  Lack of clinical efficacy of imatinib in metastatic melanoma , 2005, British Journal of Cancer.

[18]  J. Kononen,et al.  Prevalence of KIT expression in human tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Kemp,et al.  BRAF mutations in conjunctival melanoma. , 2004, Investigative ophthalmology & visual science.

[20]  D. Sidransky,et al.  Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites , 2004, Clinical Cancer Research.

[21]  N. Socci,et al.  Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.

[22]  B. Weber,et al.  Absence of BRAF mutations in UV-protected mucosal melanomas , 2004, Journal of Medical Genetics.

[23]  A. D. Van den Abbeele,et al.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  V. Prieto,et al.  Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array , 2003, Journal of cutaneous pathology.

[25]  A. Potti,et al.  Immunohistochemical determination of HER-2/neu in malignant melanoma. , 2003, Anticancer research.

[26]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[27]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[28]  D. Elder,et al.  Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[29]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[30]  Michael R. Green,et al.  Gene Expression , 1993, Progress in Gene Expression.